Immune response at birth, long-term immune memory and 2 years follow-up after in-utero anti-HBV DNA immunization

Fazio, Vito Michele; Ria, Francesco; Franco, Elisabetta; Rosati, Paolo; Cannelli, G; Signori, Emanuela; Parrella, Paola; Zaratti, Laura; Iannace, Erika; Monego, Giovanni; Blogna, S; Fioretti, Daniela Piergili; Iurescia, Sandra; Filippetti, Renzo; Rinaldi, Monica

doi:10.1038/sj.gt.3302179

Cited by 15 publications

(4 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Development of DNA vaccines against parasitic diseases shows great promise along with its safety aspects. The safety of DNA vaccines in terms of adverse effect after injection has been demonstrated in animal models and trials . These studies and trials demonstrated that the DNA vaccine platform is well tolerated and safe, as no unfavourable events were reported on host.…”

Section: Advantages and Safety Issues Related To Dna Vaccinementioning

confidence: 87%

DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control

Kumar

Samant

2016

Parasite Immunology

View full text Add to dashboard Cite

The visceral leishmaniasis (VL) caused by Leishmania donovani parasite severely affects large populations in tropical and subtropical regions of the world. The arsenal of drugs available is limited, and resistance is common in clinical field isolates. Therefore, vaccines could be an important alternative for prevention against VL. Recently, some investigators advocated the protective efficacy of DNA vaccines, which induces the T cell-based immunity against VL. The vaccine antigens are selected as conserved in various Leishmania species and provide a viable strategy for DNA vaccine development. Our understanding for DNA vaccine development against VL is not enough and much technological advancement is required. Improved formulations and methods of delivery are required, which increase the uptake of DNA vaccine by cells; optimization of vaccine vectors/encoded antigens to augment and direct the host immune response in VL. Despite the many genes identified as vaccine candidates, the disappointing potency of the DNA vaccines in VL underscores the challenges encountered in the efforts to translate efficacy in preclinical models into clinical realities. This review will provide a brief background of DNA vaccines including the insights gained about the design, strategy, safety issues, varied candidates, progress and challenges that play a role in their ability against VL.

show abstract

Section: Advantages and Safety Issues Related To Dna Vaccinementioning

confidence: 87%

DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control

Kumar

Samant

2016

Parasite Immunology

View full text Add to dashboard Cite

show abstract

“…In a fetal lamb model, memory was demonstrated to be present at least 3 months after birth [18]. Using a fetal pig model with an HBsAg DNA vaccine, immune memory was demonstrated for at least 4 months after birth [19]. Although a variety of methods are used to assess immune memory the best approach is to analyze immune responses following an immune boost with a protein antigen.…”

Section: Introductionmentioning

confidence: 98%

A single HBsAg DNA vaccination in combination with electroporation elicits long-term antibody responses in sheep

Babiuk

Tsang

Hurk

et al. 2007

Bioelectrochemistry

View full text Add to dashboard Cite

“…Their safety in terms of adverse reactions after injection has been demonstrated in animal models [38,39] as well as in human clinical trials.…”

Section: Advantages and Disadvantages Of Dna Vaccinesmentioning

confidence: 99%

DNA Vaccines: Developing New Strategies against Cancer

Fioretti

Iurescia

Fazio

et al. 2010

Journal of Biomedicine and Biotechnology

162

107

View full text Add to dashboard Cite

Due to their rapid and widespread development, DNA vaccines have entered into a variety of human clinical trials for vaccines against various diseases including cancer. Evidence that DNA vaccines are well tolerated and have an excellent safety profile proved to be of advantage as many clinical trials combines the first phase with the second, saving both time and money. It is clear from the results obtained in clinical trials that such DNA vaccines require much improvement in antigen expression and delivery methods to make them sufficiently effective in the clinic. Similarly, it is clear that additional strategies are required to activate effective immunity against poorly immunogenic tumor antigens. Engineering vaccine design for manipulating antigen presentation and processing pathways is one of the most important aspects that can be easily handled in the DNA vaccine technology. Several approaches have been investigated including DNA vaccine engineering, co-delivery of immunomodulatory molecules, safe routes of administration, prime-boost regimen and strategies to break the immunosuppressive networks mechanisms adopted by malignant cells to prevent immune cell function. Combined or single strategies to enhance the efficacy and immunogenicity of DNA vaccines are applied in completed and ongoing clinical trials, where the safety and tolerability of the DNA platform are substantiated. In this review on DNA vaccines, salient aspects on this topic going from basic research to the clinic are evaluated. Some representative DNA cancer vaccine studies are also discussed.

show abstract

Immune response at birth, long-term immune memory and 2 years follow-up after in-utero anti-HBV DNA immunization

Cited by 15 publications

References 42 publications

DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control

DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control

A single HBsAg DNA vaccination in combination with electroporation elicits long-term antibody responses in sheep

DNA Vaccines: Developing New Strategies against Cancer

Contact Info

Product

Resources

About